SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as investors discuss a potential short squeeze, with some highlighting the stock's high short interest and anticipating a breakout above the $60 resistance level. The company's recent launch of a platform for menopause and perimenopause care may be acting as a catalyst, sparking bullish sentiment, while some traders are wary of familiar resistance around the $60 mark.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast is trending as the community highlights its potential for significant growth, citing its small float and EU revenue progress. Bullish investors are actively discussing the stock's undervaluation compared to competitors and anticipating a move towards higher valuations. Positive technical indicators and upcoming Q3 earnings are fueling optimism, with some eyeing a potential short squeeze.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros ($OMER) is trending due to a surprise $2.1 billion deal with Novo Nordisk, sparking significant investor excitement. The community is focused on the potential for milestone payments and royalties, with many speculating about a potential short squeeze and a re-rating of the stock. Traders are closely watching resistance levels, debating whether to secure profits or hold for further gains based on the news.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

BITF is trending as investors discuss its strategic pivot towards high-performance computing (HPC) and AI, potentially decoupling it from Bitcoin's price action. The community highlights upcoming catalysts like the CEO's X space appearance and the company's potential to reach valuations similar to its competitors. There's also discussion around its growing power capacity and possible data center partnerships, fueling speculation about significant future growth.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

Fueled by speculation around Trump's comments on cooking oil supply chains, Sadot Group Inc. is trending with significant after-hours volatility and high relative volume. The community is actively discussing the low float and potential for a short squeeze, with some debating its long-term value amidst the recent public offering. Others point to the company's financials and potential for a bitcoin treasury strategy as reasons for optimism.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as community members discuss a recent price surge, with some attributing it to increased demand for antimony and potential government contracts. The stock experienced a significant intraday pullback, leading to speculation about short squeezes and future growth potential. Discussions also highlight UAMY's position as a key domestic supplier amid geopolitical tensions related to rare earth minerals.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as the stock experiences volatility, with community members debating potential short squeezes and the impact of partnerships. Some traders express frustration with the stock's performance and management's communication, while others remain optimistic about its long-term potential, citing undervaluation and growth prospects. Discussions also revolve around potential acquisitions and comparisons to competitors within the insurance sector.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending with significant volume as chatter swirls around a potential short squeeze and upcoming presentations at the GITEX Global conference in Dubai. Community members are actively discussing the company's AI-driven drug discovery platform and potential partnerships, with some drawing comparisons to past short squeeze events. Some are speculating about news from Dubai with others suggesting there are big investors buying in.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate the sustainability of its recent surge, with some pointing to potential market manipulation and insider selling. Concerns are rising about a possible offering or short report impacting the stock, contrasting with the continued excitement around quantum computing and the company's long-term potential. The divergence between RGTI and its peers, particularly IONQ, is fueling speculation about the factors driving the stock's price action.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor Manufacturing is trending due to anticipation surrounding its upcoming earnings report and the broader implications for the semiconductor industry, particularly in relation to AI. The community is actively discussing potential revenue and EPS numbers, with some investors buying options in anticipation of a positive earnings surprise. Additionally, there's conversation around the potential for increased AI-related chip demand, and a possible collaboration with Intel.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Futures Rise As Global Debasement Trade Sends Gold Over $4000

Futures Rise As Global Debasement Trade Sends Gold Over $4000 Futures are higher again, reversing Tuesday's modest Oracle-led decline, and are led by small caps despite additional multi billion tech...

H.C. Wainwright on Monday set a price target of $11 for CervoMed (CRVO) shares while keeping a ‘Neutral’ rating. The target implies a premium of nearly 5% from the stock’s closing price on Friday.The regulatory outlook for Neflamapimod should be clarified in the near term, the analyst told investors in a research note. The firm noted CervoMed is actively preparing for discussions with the U.S. Food and Drug Administration (FDA), which management expects to take place during the fourth quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRVO">CervoMed</a> trended in the ‘extremely bullish’ territory, while message volume is at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_12_48_27_PM_png_0e348d0430.webp" alt="CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>Late in July, Cervomed <a href="https://stocktwits.com/news-articles/markets/equity/cervomed-dementia-drug-slows-disease-progression-in-study/choeuj6R5xa">said</a> that Neflamapimod continued to slow disease progression in a type of dementia during the extension phase of its mid-stage trial. Dementia with Lewy Bodies (DLB) patients treated with Neflamapimod showed a 54% risk reduction in clinically significant worsening at week 32 of treatment, the company said.DLB is a type of dementia characterized by the presence of Lewy bodies, which are protein clumps, in the brain. It is the second most common form of neurodegenerative dementia, following Alzheimer's disease.The company then also confirmed that it is looking forward to initiating late-stage trials and is preparing to meet with the U.S. Food and Drug Administration in the fourth quarter to align on the trial design.In the second quarter of 2025, CervoMed also enrolled the first patients in a mid-stage trial of Neflamapimod in patients recovering from acute stroke. It also initiated a mid-stage trial of Neflamapimod in patients with the nonfluent/agrammatic variant of primary progressive aphasia (PPA) – a subtype of frontotemporal dementia (FTD).Neflamapimod was granted Orphan Drug designation for the treatment of FTD in November 2024. Frontotemporal dementia (FTD) is a group of brain disorders characterized by the progressive degeneration of the brain's frontal and temporal lobes, leading to changes in personality, behavior, and language.According to data from Koyfin, all six analysts covering CervoMed rate it a ‘Buy’. The stock has an average price target of $21.50.CRVO stock is up 334% this year but down approximately 36% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-stock-slips-after-us-regulator-probes-287000-chrysler-minivans/chwhGZoRdrX">Stellantis Stock Slips After US Regulator Probes 287,000 Chrysler Minivans Over Concerns Regarding Electric Power Steer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon 

Equity

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.


Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of +1,166.67% and +14.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

CervoMed Inc. (CRVO) announced on Monday that its drug continued to slow disease progression in a type of dementia during the extension phase of its mid-stage trial.Dementia with Lewy Bodies (DLB) patients treated with Neflamapimod showed a 54% risk reduction in clinically significant worsening compared to control at week 32 of treatment based on Clinical Dementia Rating Sum of Boxes, a standard measure of clinical progression in dementia trials, the company said. &nbsp;The risk reduction improved to 64% among patients with minimal Alzheimer’s disease co-pathology, it added.DLB is a type of dementia characterized by the presence of Lewy bodies, which are clumps of protein, in the brain. It is the second most common form of neurodegenerative dementia, following Alzheimer's disease.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRVO">CervoMed</a> trended in the ‘extremely bullish’ territory, while message volume is at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_28_at_12_07_40_PM_png_3051704308.webp" alt="CRVO's Sentiment Meter and Message Volume as of 12:05 p.m. ET on July 28, 2025 | Source: Stocktwits" width="626" height="60"><figcaption>CRVO's Sentiment Meter and Message Volume as of 12:05 p.m. ET on July 28, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user indicated they are awaiting analysts’ takes on the news.<stembedurl>https://stocktwits.com/generaltom/message/622721810</stembedurl>Another user praised the result and highlighted that they have loaded up on the stock.<stembedurl>https://stocktwits.com/roquefort/message/622678785</stembedurl>Lawrence S. Honig, Professor of Neurology at Columbia University Irving Medical Center, stated that this level of effect, if confirmed in a Phase 3 pivotal trial, would be an important advance in the unmet treatment needs of patients with DLB, the second most common dementia.The company is now looking forward to initiating late-stage trials and is preparing to meet with the U.S. Food and Drug Administration in the fourth quarter to align on the trial design.The firm also said that at week 32 of the extension phase, there was a statistically significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP).Plasma levels of glial fibrillary acidic protein (GFAP) are generally low in healthy individuals but can increase with certain neurological conditions.No new safety signals were identified during the extension phase of the trial, it added.CRVO stock is up by over 300% this year but down by 33% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/graphjet-ceo-says-company-expects-to-benefit-from-16.5-billion-tesla-samsung-deal/choes4fR5x3">Graphjet Stock Rockets 36% After CEO Says Company Expects To Benefit From $16.5B Tesla-Samsung Deal: Retail Wants To Buy More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of female hand touching stock market analysis digital display screen TradingView chart, analyzing investment and financial trading data in candlestick chart on a touch screen interface.

CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock

The company is now poised to initiate late-stage trials for Neflamapimod. 

CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?

CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of CervoMed Inc. (<a class="mention" data-mention="$CRVO" data-symbol-id="CRVO" href="https://stocktwits.com/symbol/CRVO" target="_blank">$CRVO</a>) jumped more than 12% in pre-market trading on Wednesday, on course to snap a two-day losing streak, and grabbed retail attention.The company announced that its oral investigational drug, neflamapimod, was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of frontotemporal dementia (FTD).Neflamapimod, currently undergoing a Phase 2b study in patients with early-stage dementia with Lewy bodies (DLB), is showing promise in targeting specific pathogenic mechanisms associated with FTD.&nbsp;The designation recognizes the drug’s potential to address a rare condition affecting approximately 50,000 to 60,000 people in the U.S., with a higher prevalence in Europe and potentially in Asia and Latin America.John Alam, CEO of CervoMed, highlighted the significance of this milestone, noting that the company is actively working with clinical experts to design a proof-of-principle study for FTD while preparing to move neflamapimod into a Phase 3 trial for DLB in mid-2025.&nbsp;The Orphan Drug status provides CervoMed with several key benefits, including tax credits for clinical trial costs, regulatory assistance, and seven years of post-approval market exclusivity.Analyst Jason Kolbert from D. Boral Capital maintained a ‘Buy’ rating on the stock, setting a price target of $34, which implies over four times upside from the stock’s previous close.<figure class="image"><a href="https://stocktwits.com/symbol/CRVO"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CRVO_sentiment_and_message_volume_Nov_27_premarket_7ed58203f3.png" alt="CRVO sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>CRVO sentiment and message volume Nov 27 premarket as of 9:15 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, the sentiment surrounding CervoMed shifted dramatically from ‘bearish’ to ‘extremely bullish,’ with a surge in message volume reflecting renewed optimism among retail investors.&nbsp;<stembedurl>https://stocktwits.com/ajmore/message/594262803</stembedurl><stembedurl>https://stocktwits.com/AnalRetort/message/594262019</stembedurl>While CervoMed’s stock has dipped 0.25% year-to-date, the latest news has reignited investor interest, propelling the stock to among the top 15 trending symbols before the bell on Wednesday.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amgn-stock-slips-premarket-after-rbc-cuts-price-target/cJI0wiDRW7">Amgen Stock Slips After More Analyst Criticism On Weight-Loss Drug Data: Retail Eyes ‘Great Buying Opportunity’</a>

Neflamapimod, currently undergoing a Phase 2b study in patients with early-stage dementia with Lewy bodies (DLB)

CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled

The Orphan Drug status provides CervoMed with several key benefits, including tax credits for clinical trial costs, regulatory assistance, and seven years of post-approval market exclusivity.

Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now

MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The...

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now

MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024...

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA.

CervoMed Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.66	--	--	N/A
Q2 '25	-$0.58	-$0.70	-20.54%	MISSED
Q1 '25	-$0.63	-$0.56	10.88%	BEAT
Q4 '24	-$0.63	--	--	N/A
Q3 '24	-$0.41	-$0.55	-33.50%	MISSED

CRVO
CervoMed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest CRVO News

CRVOCervoMed Inc